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Abstract: The monocular trial has been proposed as a test to help control for diurnal fluctua-
tions in eye pressure when assessing medication effectiveness. We undertook a prospective 
study to determine the sensitivity and specificity of the monocular trial as a test for determining 
the effectiveness of a glaucoma medication. The efficacy of the monocular trial was compared 
to the diagnostic paradigm of repeated pre- and post-treatment measurements in determining 
whether an intraocular pressure (IOP)-lowering drug is effective. Forty-two patients with newly 
  diagnosed open-angle glaucoma completed five visits: visit 1 for determining eligibility,   obtaining 
consent, and measuring IOP, visit 2 for a second pressure measurement, and visit 3 for a third 
pressure reading. The new medication was then started in one eye. IOP measurements were 
made at weeks 4 and 6. The gold standard IOP change was defined as the difference in mean 
between the pre- and post-medication visits. A medication was deemed effective if this difference 
was at least 15%. The monocular trial pressure change was defined as the IOP change in the 
treated eye between the visit immediately before and immediately after the medication addition, 
  corrected by subtracting the pressure change in the untreated eye. All 42 patients   completed the 
full protocol with good compliance. Twenty-five of 42 (60%) medication additions were con-
sidered effective by the gold standard method, and 25/42 (60%) by the monocular trial method. 
However, the two methods agreed in only 26 patients (17 Yes/Yes, 9 No/No). The calculated 
sensitivity was low (0.68), with a specificity of 0.53. The monocular trial can give useful clues 
as to whether a medication is effective, but should not be the only information used in making 
this determination. To obtain the most valid results, multiple pressure checks should be done 
before and after starting a new medication.
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Background
Glaucoma is a slowly progressive optic neuropathy with potential causative mechanisms 
related and unrelated to ocular hypertension.1,2,3 The only proven therapy for slowing 
glaucomatous visual field loss and therefore the only modifiable disease risk factor 
is through lowering of the intraocular pressure (IOP).4,5 Topical pressure-lowering 
medications are often successful at lowering the pressure to an acceptable level.6
Determining the effectiveness of IOP-lowering medications is important because 
glaucoma drugs are not equally effective in every patient, a problem for which few 
predictive parameters are available.4,7 Also, once initiated, IOP-lowering medications 
are often used throughout the lifetime of a patient.4,8,9 These drugs are costly, impact 
quality of life, and may have side effects.4,8–11 Therefore, it is incumbent on the clinician 
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to carefully assess medication effectiveness; if a drug is found 
to be ineffective it should be discontinued. Effectiveness is 
determined by comparing the intraocular pressure before 
starting a drug to the intraocular pressure after starting a 
drug.9 This sounds simple, but in clinical practice pressure 
changes can be very difficult to assess because of daily 
  fluctuations in eye pressure.12 There is a ±1–2 mmHg degree 
of uncertainty in an individual eye pressure measurement, 
and a ±3–6 mmHg variation in an individual’s eye pressure 
during the day, known as diurnal fluctuation.12–16 Considering 
these two types of variation added together, without making 
any medication changes, the pressure may be 18 mmHg on 
one day and 13 mmHg at another time point the next day 
because of normal variation and measurement inaccuracies. 
Similarly, the pressure may be 18 mmHg on one day and 
then 18 mmHg the next week after starting a medication. 
This lack of change would suggest that the medication was 
not effective, when in reality, had the pressure been as high 
as 22 without the drops, the medication could well have 
been effective. Finally, the expected change in the IOP with 
the addition of a new medication ranges from 2–10 mmHg 
depending on the initial pressure and on whether initial or 
adjunctive medications are being added. This small pressure 
change is in the same range as the sum of diurnal fluctuation 
and measurement variability in IOP. These examples show 
that any given measurement of IOP can be significantly 
altered by several different uncontrollable mechanisms, 
which results in the difficulty of determining medication 
effectiveness in the clinical setting.
To determine the effectiveness of a medication against the 
background of measurement error and diurnal fluctuation, it 
has been suggested that a monocular trial be used. Monocu-
lar trials have been used in ophthalmology for many years, 
but only recently has the term appeared in the literature on 
pressure assessment, and the monocular trial has not previ-
ously been tested against other techniques for determining 
medication effectiveness other than prostaglandins.17,18 
With a monocular trial, the pressure is taken in each eye 
before starting the new medication (ie, 23 right eyes [OD], 
25 left eyes [OS]), the drug is started in only one eye (OD, 
for example), and then the pressure is measured in each 
eye several weeks later. If the pressure in the treated eye 
decreases in relation to the pressure in the untreated eye and 
decreases .15% from the baseline pressure, the medication 
is deemed effective.19 There are several assumptions made 
with this technique.20 One is that the two eyes are closely 
correlated in their  pressure   fluctuation, and another is that 
there is no crossover effect from the medication.20,21 A recently 
published study of   glaucoma patients agrees with this first 
assumption,22 in   contrast to a prior study of healthy patients 
which   suggested that the eyes are not correlated with respect 
to IOP   fluctuation.23 With regards to the second assumption, 
there is published evidence that certain drugs, beta blockers in 
particular, do have a contralateral effect.20,24 Considering these 
issues, our current knowledge of IOP variability suggests that 
a monocular trial may not be the best means of determining 
medication effectiveness. Thus, we have performed a prospec-
tive clinical data collection to further investigate the efficacy 
of the monocular trial in determining if a particular glaucoma 
medication will be effective in comparison with the gold 
standard method of IOP measurement and treatment.
Methods and participants
The study was a prospective clinical data collection study 
approved by the Institutional Review Board of the University 
of Missouri-Kansas City. All patients signed a written consent 
to participate and the study was performed in compliance with 
the Declaration of Helsinki.25
Patients were required to have raised IOP such that the 
clinician felt that additional pressure-lowering medication 
was warranted. Abnormal visual fields and/or optic discs 
were acceptable but not necessary for enrollment. All forms 
of raised IOP were acceptable including primary open-angle 
glaucoma, pseudoexfoliation,   pigmentary   dispersion, and 
chronic angle-closure glaucoma. Conditions being treated 
with other medications (steroids, nonsteroidal anti-inflam-
matory drugs) such as uveitic glaucoma and postoperative 
pressure elevations were excluded, as pressure elevations in 
these disease states may change over a short time and interfere 
with true assessment of IOP change. IOP had to be below 
32 mmHg as higher pressures may necessitate more rapid 
intervention or the addition of multiple medications at one 
visit. The patient must have had no clinically apparent corneal 
edema or central corneal scarring which might interfere with 
applanation tonometry. Systemic medical conditions and 
medication use (such as preoperative beta-blockers) guided 
the choice of   appropriate pressure-lowering drops but were 
not exclusion criteria for the study.
Each patient completed five visits over the course of 
the study with a total time frame of 3–6 months. Visit #1 
consisted of determining eligibility, obtaining consent, and 
measuring IOP with Goldmann applanation tonometry. 
Visit #2 consisted of a second IOP measurement 1–21 days 
later. Visit #3 consisted of a third IOP measurement and 
initiation of pressure-lowering medication 1–21 days after 
visit #2. Patients in this study used any one of the following 
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medications: beta blocker, brimonidine, dorzolamide, or a 
prostaglandin. Visit #4 occurred 21–35 days after visit #3 
and consisted of an IOP measurement, the first after starting 
medication. Visit #5 occurred 1–21 days after the previous 
visit and consisted of an IOP measurement, the second after 
initiating medical therapy. At this point, if the medication was 
deemed effective it was continued and a final visit 2–3 months 
later for IOP measurement was completed.
The goal of the present study was to identify if using a 
monocular trial of a pressure-lowering medication is an accu-
rate determination of whether that medication is effectively 
lowering the IOP, when compared to multiple measurements 
of IOP before and after treatment initiation.26
Results
In all, 42 patients completed the full protocol with good 
c  ompliance. Mean IOP measurements for the treated eye 
at each visit are displayed in Figure 1 (panel A: visits 1–3; 
panel B: visits 4–5). In the treated eye, mean IOP was 
reduced from 21 mmHg before initiation of medication 
down to 16 mmHg after starting medication, resulting in 
an overall reduction of 5 mmHg, a 24% reduction in IOP. 
Thus, given this IOP reduction of .15%, medical interven-
tion was deemed effective. Of the medication additions, 
25/42 (60%) were considered effective by the gold standard 
method of multiple measurements of IOP before and after 
treatment initiation, and 25/42 (60%) by the monocular 
trial method. However, the two methods agreed in only 26 
patients (17 Yes/Yes, 9 No/No; Figure 1C). The calculated 
sensitivity was low at 0.68, with a specificity of 0.53. While 
Figure 1 shows individual values for all subjects, the indi-
vidual data sets comparing success of medical intervention 
(Figure 1C) are summarized in Figure 2.
Discussion
In our study, 42 patients with elevated eye pressure were 
treated with a pressure-lowering medication with pressure 
data recorded on three premedication visits and two post-
medication visits.
Of the 42 patients who completed our treatment protocol, 
the medication addition was considered effective in 25 when 
measured by monocular trial. The gold standard was deemed 
effective in 25/42 patients. The two methods agreed in only 26 
patients. Thus, with a low sensitivity of 0.68 and a specificity 
of 0.53, it appears that the monocular trial is less effective 
than the gold standard of multiple pre- and post- treatment 
measurements. However, the monocular trial disagreed 
with the gold standard 38% of the time, thus the monocular 
trial can be deemed an unreliable measure of medication 
effectiveness. Therefore, the gold standard of multiple mea-
surements of IOP before and after treatment initiation may 
need to be reevaluated with respect to reliable numbers for 
data points acquired before and after treatment. Perhaps a 
more statistically powerful method of treatment would be 
one in which more data points could be created, taking into 
account several pre- and post-treatment IOP measurements 
and to standardize treatments and measurements to specific 
times of day. However, we would note that in clinical practice, 
this many visits and measurements may be difficult or even 
impractical to achieve.
Despite the fact that only two prospective studies of the 
monocular trial,20,26 both with reasonably inconclusive results, 
have been published, it is still frequently used in the practice 
of treating glaucoma.26 According to a study of 26 subjects 
in 2009 by Realini, the monocular trial is not superior to the 
gold standard.26 Another more recent study, published by 
Bhorade et al in 2010 found the monocular trial not to be 
an adequate method of determining a medication’s response 
to treatment with topical prostaglandins.20 Realini’s study 
found the monocular trial to be an inadequate predictor of 
long-term IOP reduction by prostaglandins.26 Bhorade’s study 
also found the monocular trial to be an inadequate method 
of determining the patient’s response to pressure lowering 
with prostaglandins.20
Like these previous two studies, our study agrees that the 
monocular trial provides a lower statistical reliability than the 
gold standard of multiple measurements of IOP before and 
after treatment initiation, and overall is not a reliable measure 
of effectiveness.20,26 Our study included data on 42 patients, 
while Realini26 evaluated 26 subjects and Bhorade et al20 
evaluated 206. While our study evaluated only the short-term 
effect of the monocular trial in determining the efficacy of 
a given pressure-lowering medication (ie, over the course of 
2–3 months after initiating a pressure-lowering medication), 
Realini26 also measured long-term results which consisted 
of following pressure measurements for 6 months after the 
addition of the pressure-lowering medication.26 His results 
at 6 months showed the monocular trial to again be a poor 
predictor of long-term IOP reduction.26 While our study 
included patients using any class of first line pressure-  lowering 
medication, Realini26 and Bhorade et al20 only tested one 
medication, topical prostaglandins (specifically latanoprost in 
Realini).26 We feel that our results are more reflective of the 
way in which medication additions are carried out in general 
clinical practice, as patients may be using any one of various 
medication options, instead of just prostaglandins.
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Figure 1 Panel A. Intraocular pressure readings for each subject on visits 1–3. Red x, pressure on the first visit; green square, pressure on the second visit; blue circle, 
pressure on the third visit. Y-axis indicates intraocular pressure in mmHg and x-axis indicates the subject’s identification number. Panel B. intraocular pressure readings for 
each subject on visits 4–5. Red x, pressure on the fourth visit; green square, pressure on the fifth visit. Y-axis indicates intraocular pressure in mmHg and x-axis indicates the 
subject’s identification number. Panel C. A comparison of the efficacy of the monocular trial (MT) with the gold standard of multiple measurements of intraocular pressure 
before and after treatment initiation in each subject. Subpanel #1 shows that the monocular trial and the gold standard agreed on the efficacy in 17 subjects. In eight subjects, 
the gold standard was effective whereas the monocular trial was not (subpanel #2). In another eight subjects the monocular trial was deemed effective whereas the gold 
standard was not (subpanel #3). In nine subjects, neither the gold standard nor the monocular trial was deemed effective (subpanel #4).
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Overall, we concur with previous studies that the mon-
ocular trial is less effective than measuring an unadjusted 
pressure in each eye in response to treatment. However, 
the monocular trial has a practical advantage over the gold 
standard in that it requires fewer clinic visits and is thus 
more feasible. Therefore, for a subset of patients, such 
as individuals unable to attend multiple pre- and post-
medication follow-ups, the monocular trial can provide 
clues as to whether a given pressure-lowering medication 
is effective; however, it remains less effective than the 
gold standard of multiple measurements before and after 
medication initiation.
Acknowledgments
This study was supported in part by the Vision Research 
Foundation of Kansas City and the Felix and Carmen Sabates 
Missouri Endowed Chair in Vision Research (PK).
Disclosure
The authors have no financial or conflicting interests to 
declare.
References
1.  Pache M, Flammer J. A Sick eye in a sick body? Systemic findings in 
patients with primary open-angle glaucoma. Surv Ophthalmol. 2006; 
51(3):179–212.
  2.  Cedrone C, Mancino R, Cerulli A, Cesareo M, Nucci C. Epidemiology 
of primary glaucoma: prevalence, incidence, and blinding effects. Prog 
Brain Res. 2008;173:3–14.
  3.  Salim S, Shields MB. Glaucoma and systemic diseases. Surv 
  Ophthalmol. 2010;55(1):64–77.
  4.  Musch DC, Gillespie BW, Niziol LN, Cashwell LF, Lichter PR; for 
Collaborative Initial Glaucoma Treatment Study Group. Factors associ-
ated with intraocular pressure before and during 9 years of treatment in 
the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 
2008;115(6):927–933.
  5.  Thygesen J, Burk R, Carassa R, et al. Criteria for choosing clinically 
effective glaucoma treatment: A discussion panel consensus. Current 
Therapeutic Research. 2007;68(3): 127–136.
  6.  Lu VH, Goldberg I, Lu CY. Use of glaucoma medications: state of the 
science and directions for observational research. Am J Ophthalmol. 
2010;150(4):569–574.
  7.  Wilkins MR, Shah P, Khaw PT. Laser and surgical treatment of glau-
coma. In: Edgar DF, Rudnicka AR, editors. Glaucoma Identification and 
Co-management. Edinburgh: Butterworth Heinemann; 2007:171–179.
  8.  Cantor L. Achieving low target pressures with today’s glaucoma 
m  edications. Surv Ophthalmol. 2003;48(2 Suppl 1):S8–S16.
  9.  Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of 
routine office-based identification and subsequent medical treatment 
of primary open-angle glaucoma in the United States. Ophthalmology. 
2009;116(5):823–832.
  10.  Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J 
Ophthalmol. 2008;145(1):106–113.
  11.  Schwartz GF, Quigley HA. Adherence and persistence with glaucoma 
therapy. Surv Ophthalmol. 2008;53(6 Suppl 1):S57–S68.
  12.  Harper R, Henson DB. Diagnosis of the glaucomas 2: intraocular 
pressure, In: Edgar DF, Rudnicka AR, editors. Glaucoma Identifica-
tion and Co-management. Edinburgh: Butterworth Heinemann; 2007: 
107–118.
  13.  De Moraes CGV, Prata TS, Liebmann J, Ritch R. Modalities of 
tonometry and their accuracy with respect to corneal thickness and 













Figure 2 Agreement between monocular trial and gold standard of multiple measurements of intraocular pressure before and after treatment initiation with regards to 
efficacy. This chart shows that the monocular trial was deemed effective in 25/42 patients (blue circle) and the gold standard was deemed effective in 25/42 patients (red 
circle). These two methods agreed in 17 patients (the area in between the blue and red circles).




Efficacy of monocular trial treatment in primary open-angle glaucomaClinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2012:6
  14.  Baskaran M, Rajesh S. Kumar RS, et al. Diurnal intraocular pressure 
fluctuation and associated risk factors in eyes with angle closure.   
Ophthalmology. 2009;116(12):2300–2304.
 15.  Werne A, Harris A, Moore D, BenZion I, Siesky B. The circadian variations 
in systemic blood pressure, ocular perfusion pressure, and ocular blood 
flow: risk factors for glaucoma? Surv Ophthalmol. 2008;53(6):559–567.
  16. Liang SYW, Lee GA, Shields D. Self-tonometry in glaucoma 
  management – past, present and future. Surv Ophthalmol. 2009;54(4): 
450–462.
  17.  Feibel RM. Monocular Drug Trial. Ophthalmology. 2010;117(5):1048.
  18.  Sawamura MH. Challenging the validity of the monocular trial. 
  Optometry. 2009;80(4):165–166.
  19.  Vetrugno M, Cantatore F, Ruggeri G, et al. Primary open angle glau-
coma: an overview on medical therapy. Prog Brain Res. 2008;173: 
181–193.
  20.  Bhorade AM, Wilson BS, Gordon MO, et al; for Ocular Hyperten-
sion Treatment Study Group. The utility of the monocular trial: 
data from the ocular hypertension treatment study. Ophthalmology. 
2010;117(11):2047–2054.
  21.  Realini T, Vickers WR. Symmetry of fellow-eye intraocular pres-
sure responses to topical glaucoma medications. Ophthalmology. 
2005;112(4):599–602.
  22.  Sit AJ, Liu JH, Weinreb RN. Asymmetry of right versus left intraocular 
pressures over 24 hours in glaucoma patients. Ophthalmology. 2006; 
113(3):425–430.
  23.  Sit AJ, Liu JH, Weinreb RN. Variation of 24-hour intraocular 
pressure in healthy individuals. Ophthalmology. 2005;112(10): 
1670–1675.
  24.  American Academy of Ophthalmology. Primary Open-Angle Glaucoma 
Preferred Practice Pattern. San Francisco: American Academy of Oph-
thalmology; 2000. Available from: http://one.aao.org/CE/PracticeGuide-
lines/PPP_Content.aspx?cid=e2387c8a-e51c-4c21-be20-c30fbf4f3260. 
Accessed February 10, 2012.
  25.  wma.net [homepage on the Internet] World Medical Association. 
  Declaration of Helsinki. Ethical Principles for Medical Research 
Involving Human Subjects. [5 pages] Available from. http://www.wma.
net/en/30publications/10policies/b3/17c.pdf. Accessed February 14, 
2012.
  26.  Realini TD. A Prospective, randomized, investigator-masked evaluation 
of the monocular trial in ocular hypertension or open-angle glaucoma. 
Ophthalmology. 2009;116(7):1237–1242.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
496
Krishna et al